ArticleCancer2020

Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.

Megan E V Caram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.